Boehringer Ingelheim International GmbH : Strategic SWOT and PESTLE Analysis - A 360° Review of Opportunities, Challenges and Risk, Corporate and ESG Strategies, Competitive Intelligence, and Recent Trends

Boehringer Ingelheim International GmbH : Strategic SWOT and PESTLE Analysis - A 360° Review of Opportunities, Challenges and Risk, Corporate and ESG Strategies, Competitive Intelligence, and Recent Trends


Report Summary

Boehringer Ingelheim International GmbH : Strategic SWOT and PESTLE Analysis - A 360° Review of Opportunities, Challenges and Risk, Corporate and ESG Strategies, Competitive Intelligence, and Recent Trends Report is a comprehensive and easily accessible overview of Boehringer Ingelheim International GmbH's business operations. It provides a detailed analysis of the company's strategic standing, as well as its position in the industry compared to competitors. The report includes several key features to facilitate decision-making and provide insights into the company's performance.

The report begins with in-depth information about Boehringer Ingelheim International GmbH including key insights, business segments, key executives, locations, products and services, historical events, corporate strategy, and management discussions. This section provides a solid foundation for understanding the company's key attributes.

Next, the report assesses Boehringer Ingelheim International GmbH's strategic standing through various analyses. The ESG spotlight evaluates the company's environmental, social, and governance performance, providing insights into its sustainability efforts and ethical practices. The SWOT analysis examines the company's internal strengths and weaknesses, as well as external opportunities and threats. The PESTLE analysis evaluates the external factors impacting the company's operations and market environment. Additionally, By integrating these strategic analyses, the report offers a comprehensive understanding of Boehringer Ingelheim International GmbH's overall strategic standing and supports informed decision-making and strategic planning.

Finally, the report includes recent news and deal activities undertaken by Boehringer Ingelheim International GmbH enhancing awareness of the company's business trends, growth perspectives, and more.

Key Highlights

Boehringer Ingelheim International GmbH operates as a subsidiary of C. H. Boehringer Sohn AG and Co. KG. Boehringer Ingelheim International GmbH operates in the pharmaceuticals segment for humans and animals as well as contract development and manufacturing services. Boehringer Ingelheim International GmbH engages in the research, development, and marketing of drugs for humans and animals. It offers cardiovascular, respiratory, oncology, immunology, metabolic diseases, retinal health, and central nervous system products. The company also offers pharmaceutical products for companion animals and livestock. Additionally, it offers tailor-made contract development and manufacturing services to the biopharmaceutical industry. Founded in 1885, the company is headquartered in Ingelheim am Rhein, Rhineland-Palatinate, Germany.

Boehringer Ingelheim International GmbH in the News:-
  • 2024-04-18 - Boehringer Ingelheim introduces NexGard SPECTRA for dogs in India
  • 2024-04-09 - Boehringer Ingelheim Biopharmaceuticals China receives approval for supply of EU and US markets
  • 2024-02-14 - Jardiance (empagliflozin) now approved in India for the treatment of adults with chronic kidney disease
  • 2024-02-01 - Boehringer Ingelheim India earns Top Employer 2024 accolade for second consecutive year
  • 2023-09-20 - Boehringer Ingelheim India joins forces with Pet Practitioners Association of Mumbai (PPAM) and Brihanmumbai Municipal Corporation (BMC) to ‘Stop Rabies’ in Mumbai
Scope
  • Tactical Analysis:- Various strategic frameworks to gain insights into a company's competitive position and operational environment. These analytical tools assist in identifying competitive advantages, potential risks, and areas for improvement and efficiency, enabling companies to make informed tactical decisions.
  • Business Strategy:- Contributes to shaping the company's overall direction, goals, and decision-making processes, ensuring long-term success and alignment with stakeholder expectations.
  • Company Fundamentals:- These fundamentals offer valuable insights into the company's history, operations, leadership, and geographical presence, aiding in a comprehensive understanding of the organization.
  • Competitive Landscape:- An identification of the company's main competitors, providing insights into the competitive landscape it operates in.
Reasons to Buy
  • Comprehensive Understanding of the Boehringer Ingelheim International GmbH's internal and external factors through SWOT analysis, PESTLE analysis and Competitors Benchmarking.
  • Strive Strategic Decision Making with various analyses and identifying potential customers and suppliers.
  • Mitigate Risk with help of thorough analysis of internal and external factors. Furthermore, develop strategies and contingency plans to address these challenges and minimize their impact on business operations.
  • Competitive Benchmarking will help to gain a competitive advantage by understanding industry trends, customer preferences, and best practices.
  • Valuable insights from the report enable investors and partners to make informed decisions regarding potential Collaborations, Investments, or Partnerships with the company.
Additionally, available deep-dive analysis on the company Boehringer Ingelheim International GmbH:
  • Boehringer Ingelheim International GmbH Value Chain Analysis
  • Boehringer Ingelheim International GmbH Porter's Five Forces Analysis
  • Boehringer Ingelheim International GmbH VRIO Analysis
  • Boehringer Ingelheim International GmbH BCG Analysis
  • Boehringer Ingelheim International GmbH Segmentation, Targeting and Positioning (STP) Analysis
  • Boehringer Ingelheim International GmbH Ansoff Matrix Analysis


Tables
Charts
Boehringer Ingelheim International GmbH - Key Company Facts
Boehringer Ingelheim International GmbH - Company Description
Boehringer Ingelheim International GmbH - Top Executives
Boehringer Ingelheim International GmbH - Top Executives Biographies
Boehringer Ingelheim International GmbH - Head Office & Locations
Head Office - Country
Key Subsidiaries
Key Joint Ventures
Boehringer Ingelheim International GmbH - Products and Services
Products
Boehringer Ingelheim International GmbH - Historic Events
Boehringer Ingelheim International GmbH - Company’s Management Discussion
Boehringer Ingelheim International GmbH - Company’s Mission and Vision
Vision
Boehringer Ingelheim International GmbH - Corporate Strategy
Boehringer Ingelheim International GmbH - Business Description
Human Pharmaceuticals
Animal Health
Biopharmaceutical Contract Manufacturing
Other Sales
Boehringer Ingelheim International GmbH - ESG Spotlight
Environment
Social
Corporate Governance
Boehringer Ingelheim International GmbH - SWOT Analysis
Overview
Strengths
Weaknesses
Opportunities
Threats
Boehringer Ingelheim International GmbH - PESTLE Analysis
Overview
Political Factors
Economic Factors
Social Factors
Technological Factors
Legal Factors
Environmental Factors
Competing Players
Snapshot of Competing Players
AstraZeneca Plc
Key Company Facts
Company Description
GSK plc
Key Company Facts
Company Description
Novartis AG
Key Company Facts
Company Description
Pfizer Inc.
Key Company Facts
Company Description
Sanofi SA
Key Company Facts
Company Description
Boehringer Ingelheim International GmbH - In the News
18-Apr-2024 - Boehringer Ingelheim introduces NexGard SPECTRA for dogs in India
09-Apr-2024 - Boehringer Ingelheim Biopharmaceuticals China receives approval for supply of EU and US markets
14-Feb-2024 - Jardiance (empagliflozin) now approved in India for the treatment of adults with chronic kidney disease
01-Feb-2024 - Boehringer Ingelheim India earns "Top Employer 2024" accolade for second consecutive year
20-Sep-2023 - Boehringer Ingelheim India joins forces with Pet Practitioners Association of Mumbai (PPAM) and Brihanmumbai Municipal Corporation (BMC) to ‘Stop Rabies’ in Mumbai
05-Sep-2023 - New partnership working on solutions to combat African animal trypanosomiasis
17-Aug-2023 - Boehringer Ingelheim to advance survodutide into three global Phase III studies in obesity
14-Aug-2023 - Boehringer Ingelheim receives FDA approval for SENVELGO® (velagliflozin oral solution): the first oral liquid medication for diabetes in cats
20-Jul-2023 - Boehringer Ingelheim Receives FDA Approval for NexGard® PLUS (afoxolaner, moxidectin and pyrantel chewable tablets): A Beef-Flavored Soft Chew That Protects Dogs from Internal and External Parasites
09-May-2023 - Boehringer Ingelheim Begins Clinical Development of First-In-Class Treatment for Fibrotic Diseases
24-Apr-2023 - Boehringer Ingelheim inaugurates largest European development centre for biotechnology
29-Mar-2023 - Boehringer Ingelheim reaches more patients than ever in 2022 as innovative medicines drive growth
19-Dec-2022 - Boehringer Ingelheim and Click Therapeutics expand their existing Collaboration to develop Prescription Digital Therapeutics for Schizophrenia
06-Sep-2022 - Boehringer Ingelheim launches Fencovis®, a new vaccine to prevent calf diarrhea
14-Jun-2022 - Boehringer Ingelheim and CarthroniX announce partnership to pursue small molecule therapeutics in canine oncology
Boehringer Ingelheim International GmbH - Key Deals
14-Jun-2022 - Boehringer Ingelheim signs Option to Acquire Trutino Biosciences
Appendix
Definitions
SWOT Analysis
PESTLE Analysis
Value Chain Analysis
ESG Spotlight
Research Methodology
Disclaimer
Contact Us
Tables
Table 1: Boehringer Ingelheim International GmbH - Company Facts
Table 2: Boehringer Ingelheim International GmbH - Top Executives
Table 3: Boehringer Ingelheim International GmbH - Top Executives Biographies
Table 4: Boehringer Ingelheim International GmbH - Subsidiaries
Table 5: Boehringer Ingelheim International GmbH - Key Joint Ventures
Table 6: Boehringer Ingelheim International GmbH - Products
Table 7: Boehringer Ingelheim International GmbH - Historic Events
Table 8: Boehringer Ingelheim International GmbH - Competing Players
Table 9: Competing Players - AstraZeneca Plc - Key Company Facts
Table 10: Competing Players - AstraZeneca Plc - Key Financials
Table 11: Competing Players - GSK plc - Key Company Facts
Table 12: Competing Players - GSK plc - Key Financials
Table 13: Competing Players - Novartis AG - Key Company Facts
Table 14: Competing Players - Novartis AG - Key Financials
Table 15: Competing Players - Pfizer Inc. - Key Company Facts
Table 16: Competing Players - Pfizer Inc. - Key Financials
Table 17: Competing Players - Sanofi SA - Key Company Facts
Table 18: Competing Players - Sanofi SA - Key Financials
Charts
Figure 1: Boehringer Ingelheim International GmbH - SWOT Analysis
Figure 2: Boehringer Ingelheim International GmbH - PESTLE Analysis
Figure 3: Competing Players - AstraZeneca Plc - Key Financials
Figure 4: Competing Players - GSK plc - Key Financials
Figure 5: Competing Players - Novartis AG - Key Financials
Figure 6: Competing Players - Pfizer Inc. - Key Financials
Figure 7: Competing Players - Sanofi SA - Key Financials

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings